Abstract
Osteopontin (OPN) was suggested to have a role in the pathophysiology of MS and in
bone metabolism. However, we formerly reported increased presence of osteoporosis
in MS patients independent of corticosteroid treatment, there is only limited information
about the mechanism of bone loss. In this study, we investigated the role of OPN on
bone mineral density in MS patients. Thirty-three relapsing–remitting (RR), 12 secondary
progressive (SP), and 5 primary progressive (PP) MS patients and 30 healthy controls
were prospectively enrolled. Students' t test, chi-square test, and Pearson correlations were used. The mean OPN level was
155.4±81.8 ng/ml in controls, and 15.9±36.2 ng/ml in MS patients (p<0.001).No statistical difference was observed among RR, SP and PPMS patients (p=0.162). No relationship was found between OPN levels and age at onset of disease (p=0.830), gender (p=0.785), MS subtypes (p=0.330), disease duration (p=0.744), or EDSS scores (p=0.633).About 34% of MS patients versus 10.3% of controls had osteoporosis (p=0.017).Osteopontin levels showed no significant correlation with osteoporosis in controls,
but were lower in MS patients with osteoporosis in femur neck (r=0.85, p=0.010).The cumulative dose of corticosteroid treatment did not correlate with OPN
levels (p=0.285).In conclusion, our results suggest that OPN may have a role as a shared cytokine
in pathogenesis of MS and osteoporosis.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Plasma osteopontin levels in multiple sclerosis.J Neuroimmunol. 2005; 158: 231-239
- Identifying disease modifying genes in multiple sclerosis.J Neuroimmunol. 2002; 123: 144-159
- Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients.J Neuroimmunol. 2003; 136: 125-129
- The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro.J Clin Invest. 1995; 95: 713-724
- Induction and temporal changes of osteopontin mRNA and protein in the brain following systemic lipopolysaccharide injection.J Neuroimmunol. 2007; 141: 74-83
Choi JS, Park HJ, Cha JH, Chung JW, Chun MH, Lee MY., Induction and temporal changes of osteopontin mRNA and protein in the brain following systemic lipopolysaccharide injection. J Neuroimmunol 2003: 141:65-73.
- Multiple sclerosis: a two-stage disease.Nature Immunol. 2001; 2: 762-764
- Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system.Cell. 1996; 85: 299-302
- Comment on “The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease”.Science. 2003; 299: 1845
- The osteopontin — CD44 pathway is superfluous for the development of autoimmune myocarditis.Eur J Immunol. 2006; 36: 494-499
- Osteopontin gene and clinical severity of multiple sclerosis.J Neurol. 2003; 25: 943-947
- Osteopontin polymorphisms and disease course in multiple sclerosis.Genes Immun. 2003; 4: 312-315
- The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease.Science. 2001; 294: 1731-1735
- Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice.J Immunol. 2002; 168: 2096-2099
- Osteopontin expression and function: role in bone remodeling.J Cell Biochem. 1998; 31: 92-102
- cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN).Genomics. 1990; 7: 491-502
- Osteopontin is associated with nuclear factor κB gene expression during tail-suspension-induced bone loss.Exp Cell Res. 2006; 312: 3075-3083
- Osteopontin: a bridge between bone and the immune system.J Clin Invest. Jul 2003; 112: 147-149
- Bone status in multiple sclerosis: beyond corticosteroids.Mult Scler. 2003; 9: 600-604
- Review: cytokines and the pathogenesis of multiple sclerosis.J Neurosci Res. 1996; 45: 322-333
- Elevated osteopontin levels in active relapsing–remitting multiple sclerosis.Ann Neurol. 2003; 53: 819-822
- Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules.Brain. 1999; 122: 2297-2307
- Serum soluble adhesion molecules in multiple sclerosis: raised sVCAM-1, sICAM-1 and sE-selectin in primary progressive disease.J Neurol. 1999; 246: 87-92
- Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging.Neurology. 1997; 48: 1557-1565
- Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.Ann Neurol. 2000; 47: 707-717
- Osteopontin levels and increased disease activity in relapsing–remitting multiple sclerosis patients.J Neuroimmunol. 2004; 155: 155-160
- Fracture history and bone loss in patients with MS.Neurology. 1998; 51: 1161-1165
- High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis.Neurology. 1994; 44: 1687-1692
- Sporadic glucocorticoid pulses and osteoporosis in multiple sclerosis.Arch Neurol. 1996; 53: 753-757
- Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid use.Calcif Tissue Int. 1997; 61: 129-133
- Differential aspects of cytokines in the immunopathology of MS.Neurology. 1995; 45: 4-5
- Bone and cytokines: beyond IL-1, 11-6 and TNF-a.Calcif Tissue Int. 1999; 64: 1-7
- Osteopontin: a protein with diverse functions.FASEB J. 1993; 7: 1475-1482
- Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene.Crit Rev Immunol. 1993; 13: 225-246
- Osteopontin gene halotypes correlate with multiple sclerosis development and progression.J Neuroimmunol. 2005; 163: 172-178
Article info
Publication history
Accepted:
August 20,
2008
Received in revised form:
July 21,
2008
Received:
March 29,
2008
Identification
Copyright
© 2008 Elsevier B.V. Published by Elsevier Inc. All rights reserved.
